Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 38Thoracic 6CNS 4Other solid neoplasm 3Sarcoma 2Head & Neck 2Gastrointestinal 2Endocrine 2NET 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Sarcoma 200Osteosarcoma 74Sarcoma, Ewing 50Rhabdomyosarcoma 48Melanoma 42Neuroblastoma 38Gastrointestinal Stromal Tumors 35Neoplasms 34Neoplasm Metastasis 32Bone Neoplasms 32Colorectal Neoplasms 31Glioblastoma 29Breast Neoplasms 25Ovarian Neoplasms 24Wilms Tumor 23Rhabdoid Tumor 23Gliosarcoma 23Glioma 23Liposarcoma 22Carcinoma, Non-Small-Cell Lung 22Lymphoma, Non-Hodgkin 21Sarcoma, Kaposi 20Neurofibrosarcoma 20Carcinoma, Renal Cell 20Pancreatic Neoplasms 19Medulloblastoma 19Hepatoblastoma 19Desmoid Tumors 18Thyroid Neoplasms 17Lymphoma 17

Interventions

LY2940680 1Imatinib Mesylate 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uveal Melanoma × Sarcoma × 90 days × Clear all
NCT01046487 2026-03-13

PALANGI3

Centre Oscar Lambret

Phase 1 Completed
26 enrolled
DermatologicGastrointestinalSarcoma

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡